SS-31 Dosage: How Much to Take, When & How

SS-31 Dosage: How Much to Take, When & How

Overview

SS-31 (Elamipretide) is a mitochondria-targeting tetrapeptide administered exclusively via injection to address mitochondrial dysfunction underlying heart failure, renal ischemia-reperfusion injury, age-related mitochondrial decline, and neurodegenerative conditions. As an investigational compound without FDA approval, dosing protocols derive from clinical trials, with standard ranges between 0.1–0.5 mg/kg or fixed doses of 4–40 mg administered once daily via injection.

This guide provides practical dosing information for those researching SS-31, with emphasis on actual dose amounts, administration frequency, timing strategies, and cost considerations. This content is educational only and does not constitute medical advice. SS-31 remains investigational; any use outside approved clinical trials carries significant safety and legal risks.

Standard Dosing Protocol

The established dosing framework for SS-31 spans two approaches:

Weight-Based Dosing:

• 0.1–0.5 mg/kg administered once daily via injection
• For a 70 kg individual: 7–35 mg per dose
• For an 80 kg individual: 8–40 mg per dose
• For a 60 kg individual: 6–30 mg per dose

Fixed Dose Regimen:

• 4 mg once daily (lower end, typically for initial tolerance assessment)
• 40 mg once daily (higher end, used in most efficacy-demonstrating trials)
• Intermediate doses of 20 mg once daily (common maintenance dose)

Frequency: All clinical trial protocols employed once-daily dosing, typically administered in the morning to align with natural circadian mitochondrial activity patterns, though specific timing flexibility exists within the 24-hour window.

Duration: Most human trials employed treatment periods ranging from 4 weeks to 28 weeks. Limited data exists beyond 12 months, making extended protocols speculative without direct clinical evidence.

Dosing by Goal

Different research objectives and mitochondrial conditions warrant adjusted dosing strategies:

Heart Failure & Cardiac Dysfunction

Clinical trials in heart failure employed:

• Single 4-hour IV infusions at 0.25 mg·kg⁻¹·h⁻¹ (highest dose tested)
• Daily subcutaneous injection of 4 mg or 40 mg over 28 days

The highest dose (0.25 mg·kg⁻¹·h⁻¹ as continuous infusion) demonstrated the most consistent cardiac improvements, reducing left ventricular end-systolic volume by 14 mL. However, subsequent 28-day trials at fixed doses (4–40 mg daily) showed mixed results, suggesting acute, higher-dose infusion may outperform daily subcutaneous injection for cardiac endpoints.

Mitochondrial Myopathy & Exercise Capacity

The most robust human efficacy data come from primary mitochondrial myopathy trials:

• Highest dose tested: 0.25 mg/kg/hour IV infusion
• Standard subcutaneous dose: 40 mg daily
• Effect: 19.8–64.5 m improvement in 6-minute walk test, with higher doses trending toward significance
• Duration: 4–28 weeks continuous dosing

Barth Syndrome & Sustained Functional Improvement

• Fixed dose: 40 mg daily via subcutaneous injection
• Duration: 168 weeks (open-label extension)
• Effect: 96.1 m cumulative improvement in 6-minute walk test by week 168 (p=0.003)
• This represents the longest sustained human use, supporting 40 mg daily as a long-term maintenance dose

Renal Ischemia-Reperfusion Injury & Post-Operative Renal Protection

• Dose employed: Not explicitly specified in published summary, but consistent with standard protocols
• Timing: Administered peri-operatively
• Effect: -6% post-operative hypoxia decline (vs +47% placebo) and 30% increase in renal blood flow

Age-Related Mitochondrial Decline & Energy Support

For aging tissues and age-associated mitochondrial dysfunction:

• Standard maintenance: 20–40 mg daily
• Duration: 8–12 weeks followed by reassessment
• Rationale: In-vitro studies in aged human bone marrow stem cells showed 35% increase in ATP production at moderate peptide concentrations; human dosing extrapolation suggests 20–40 mg range

How to Administer

SS-31 is injection-only and does not have oral or inhalation formulations.

Injection Route:

Subcutaneous (SC) injection is the standard route for ongoing use:

• Needle gauge: 27–30G typically appropriate for subcutaneous peptides
• Injection sites: Rotate between abdomen, thigh, and upper arm to minimize injection site reactions
• Volume: Fixed doses of 4–40 mg are typically delivered in 0.5–1.0 mL volumes depending on concentration
• Timing: Administer at the same time each day, preferably in the morning

Intravenous (IV) Infusion:

Reserved for acute or high-dose protocols:

• Infusion rate: 0.25 mg·kg⁻¹·h⁻¹ over 4 hours (single dose) was employed in cardiac trials
• Concentration: Prepared by clinical pharmacy or specialized compounding services
• Setting: Hospital or clinical infusion center required

Storage & Handling:

• Storage temperature: 2–8°C (refrigerated)
• Stability: Typically 2–4 weeks once reconstituted, depending on formulation
• Sterility: Must be prepared under aseptic conditions; pre-filled syringes from licensed compounders only
• Do not freeze after reconstitution

Injection Site Reactions:

• Incidence: 30–40% in trials, primarily erythema, induration, and transient pain
• Onset: Usually within 24 hours of injection
• Duration: Resolves within 48–72 hours typically
• Mitigation: Rotate injection sites, ensure proper needle depth, apply light pressure post-injection

Cycling & Timing Strategies

Limited human data exists regarding optimal cycling protocols. Available trial structures inform reasonable approaches:

Continuous Daily Dosing (Evidence-Supported)

• Duration: 4–28 weeks continuous, once daily
• Best for: Acute conditions, mitochondrial myopathy, heart failure
• Rationale: All positive efficacy trials employed uninterrupted daily dosing
• Discontinuation: No taper required based on available data; abrupt cessation appears safe

Long-Term Maintenance Dosing

• Dose: 20–40 mg daily
• Duration: 12+ weeks (limited data beyond 12 months)
• Protocol: Continuous without planned off-cycles
• Monitoring: Periodic reassessment of efficacy every 8–12 weeks recommended

Pulsed/Intermittent Dosing (Speculative)

• Not studied in published human trials
• Theoretical benefit: May reduce cumulative exposure while maintaining mitochondrial benefits
• Example protocol (unsupported): 4 weeks on, 1–2 weeks off
• Caution: No human data supports efficacy; continuous dosing remains standard

Dose Escalation

When initiating SS-31:

• Week 1: 4 mg daily (tolerance assessment)
• Week 2–4: 10–20 mg daily (standard range)
• Week 5+: 20–40 mg daily (efficacy-supporting dose)

This gradual escalation allows monitoring for adverse effects while accommodating individual tolerance.

Beginner vs Advanced Dosing

Beginner Protocol (Initial Exposure)

• Starting dose: 4 mg once daily via subcutaneous injection
• Duration: 1–2 weeks at this dose
• Objective: Assess tolerability, monitor for injection site reactions, establish injection technique
• Cost: ~$10–$20 for 2 weeks (depending on supplier pricing)
• Advancement: Increase to 20 mg daily if tolerated

Intermediate Protocol (Standard Efficacy Dose)

• Dose: 20 mg once daily via subcutaneous injection
• Duration: 4–12 weeks
• Objective: Target mitochondrial dysfunction with moderate peptide exposure
• Cost: ~$80–$200 per month
• Efficacy expectation: Modest improvements in exercise capacity and energy; improved fatigue in mitochondrial myopathy

Advanced Protocol (High-Dose, Short Duration)

• Dose: 40 mg once daily for 4 weeks, then reassess
• Alternative: 0.25 mg/kg/h as 4-hour IV infusion (clinical setting only)
• Objective: Maximize acute mitochondrial benefit; may be preferable for heart failure or acute injury recovery
• Cost: ~$200–$400 per month for 40 mg daily
• Efficacy expectation: Greatest effect on exercise capacity; strongest cardiac improvements in trials

Extended Protocol (Long-Term Maintenance)

• Dose: 20–40 mg once daily, continuous
• Duration: 12+ weeks (up to 168 weeks documented in Barth syndrome)
• Objective: Sustained mitochondrial support for chronic conditions
• Cost: $80–$400 per month depending on dose
• Efficacy expectation: Cumulative benefits in exercise capacity and functional outcomes over extended periods

Common Dosing Mistakes

Underdosing

Doses below 4 mg daily or infrequent administration (less than daily):

• Error impact: Insufficient mitochondrial targeting; diminished cardiolipin binding
• Result: Minimal efficacy; wasted cost
• Solution: Maintain minimum 4 mg daily, once daily

Exceeding 0.5 mg/kg

Calculating doses above 0.5 mg/kg:

• Error impact: No efficacy trials exceed this threshold; safety profile at higher levels unknown
• Result: Increased injection site reactions, unknown systemic effects
• Solution: Cap dose at 0.5 mg/kg or 40 mg fixed maximum

Inconsistent Daily Timing

Varying injection time by >6 hours daily:

• Error impact: Reduces steady-state mitochondrial peptide concentration
• Result: Suboptimal cardiolipin binding; inconsistent efficacy
• Solution: Administer at the same clock time each day (±1–2 hours acceptable)

Non-Sterile Reconstitution or Injection

Self-preparing from powder or reusing needles:

• Error impact: Bacterial contamination; local and systemic infection risk
• Result: Injection site abscess, sepsis
• Solution: Use only pre-filled syringes from licensed compounders; single-use needles only

Immediate Discontinuation Without Observation Period

Stopping after 1–2 weeks due to injection site reactions:

• Error impact: Injection site reactions are transient and expected (30–40% incidence); premature discontinuation foregoes efficacy
• Result: Loss of therapeutic opportunity; incomplete assessment
• Solution: Continue 4–6 weeks minimum with site rotation before judging efficacy or tolerability

Cycling Too Frequently

Alternating on/off protocols without evidence:

• Error impact: Prevents accumulation of mitochondrial-protective effects; frequent disruptions to cardiolipin stabilization
• Result: Minimal sustained benefit
• Solution: Commit to continuous daily dosing for minimum 4 weeks before any off-cycles

Summary Dosing Table

Final Considerations

Cost-Benefit Analysis

At $80–$400 monthly depending on dose selection, cost represents a significant consideration. Entry at 4 mg daily (~$80/month) permits low-cost tolerance assessment before advancing to 20–40 mg doses ($150–$400/month).

Legal & Regulatory Status

SS-31 remains investigational without FDA approval for any indication. Procurement outside clinical trials occurs through compounding pharmacies; verify licensing and source legitimacy before use. Self-injection outside clinical supervision carries inherent risks regarding sterility, dosing accuracy, and unmonitored systemic effects.

Individual Variation

Weight, age, body composition, and baseline mitochondrial function influence optimal dosing. Individuals <60 kg may achieve efficacy at 4–20 mg daily, while those >90 kg may benefit from 30–40 mg. Personalized starting assessment remains advisable.

Monitoring & Adjustment

Efficacy assessment requires 4–6 weeks minimum before dose adjustments. Markers include subjective energy, exercise capacity (6-minute walk test if available), fatigue scores, and injection site tolerability. Doses may be increased by 5–10 mg every 2–4 weeks if needed and tolerated.

Disclaimer: This guide is for educational purposes only and does not constitute medical advice, clinical recommendation, or endorsement of use. SS-31 is an investigational compound without FDA approval. Any use outside regulated clinical trials is at individual risk and should be undertaken only under medical supervision with full informed consent regarding unknown long-term safety profiles, lack of manufacturing standardization, and potential contaminants in non-pharmaceutical-grade peptides. Consult a qualified healthcare provider before initiating any peptide protocol.